Davis Funds, an investment management firm, released its “Davis New York Venture Fund” third quarter 2023 investor letter, a copy of which can be downloaded here. During the initial seven months, ending on July 31, 2023, the fund yielded a return of 25.38%. This recent performance of the fund aligns with the burst of the easy-money bubble, which originated in the wake of the financial crisis and gained momentum throughout the pandemic. Take a moment to review the fund’s top 5 holdings to gain insights into their primary investment choices for 2023.
In its Q3 2023 investor letter, Davis New York Venture Fund mentioned Viatris Inc. (NASDAQ:VTRS) and explained its insights for the company. Viatris Inc. (NASDAQ:VTRS) is a Canonsburg, Pennsylvania-based pharmaceutical company with an $11.1 billion market capitalization. Viatris Inc. (NASDAQ:VTRS) delivered a -16.71% return since the beginning of the year, while its 12-month returns are down by -4.43%. The stock closed at $9.27 per share on November 3, 2023.
Here is what Davis New York Venture Fund has to say about Viatris Inc. (NASDAQ:VTRS) in its Q3 2023 investor letter:
“In the attractive healthcare sector, we look beyond the obvious to identify businesses that simultaneously have exposure to this growth industry and also trade at low prices. We’re especially drawn to companies like Viatris, whose products or services play a part in helping to mitigate healthcare’s constantly rising costs. The healthcare industry has been a growing part of the U.S. economy for decades. As a result, many companies in this sector trade at high valuations reflecting their robust but well-known reputation for growth. For value-conscious investors like us, investing in healthcare requires looking beyond the obvious to identify businesses that have exposure to this growth industry but which trade at low prices. Furthermore, recognizing that the constantly rising cost of healthcare cannot go on forever, we have been particularly drawn to companies whose products or services play some role in managing or reducing the cost of care. As a result, we have positions in Viatris, a leading manufacturer of low-cost branded generic drugs .
A pharmacist holding a vial of a pharmaceutical product manufactured by West Pharmaceuticals.
Our calculations show that Viatris Inc. (NASDAQ:VTRS) failed to make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Viatris Inc. (NASDAQ:VTRS) was in 42 hedge fund portfolios at the end of the second quarter of 2023, compared to 46 funds in the previous quarter. Viatris Inc. (NASDAQ:VTRS) delivered a -12.46% return in the past 3 months. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters Q3 2023 page.
Suggested Articles:
- 25 Worst States for Human Trafficking in America
- 20 Most Common Places to Get Kidnapped
- 20 Least Diverse Countries in the World
Disclosure: None. This article is originally published at Insider Monkey.
